Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8398-8411

  Remen, Lubos ^a   Bezençon, Olivier ^a   Simons, Lloyd ^b   Gaston, Rick ^b   Downing, Dennis ^b   Gatfield, John ^a   Roch, Catherine ^a   Kessler, Melanie ^a   Mosbacher, Johannes ^a   Pfeifer, Thomas ^a   Grisostomi, Corinna ^a   Rey, Markus ^a   Ertel, Eric A ^a   Moon, Richard ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Kalexsyn Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; DIHYDROPYRAZOLE DERIVATIVE; N,5 BIS(4 FLUOROPHENYL) 3 (PYRIDIN 4 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOLATERAL AMYGDALA; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROCARDIOGRAPHY; HUMAN; HUMAN CELL; KINDLING; MALE; NONHUMAN; PR INTERVAL; RAT; TEMPORAL LOBE EPILEPSY; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; DOG; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EPILEPSY; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; BRAIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DISEASE MODELS, ANIMAL; DOGS; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; KINDLING, NEUROLOGIC; MALE; PYRAZOLES; RATS, WISTAR;

EID: 84988735529     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00756     Document Type: Article

References (71)

1. World Health Organization. Media Centre. http://www.who.int/mediacentre/factsheets/fs999/en/.
2. Berg, A. T.; Scheffer, I. E. New concepts in classification of the epilepsies: entering the 21st century Epilepsia 2011, 52, 1058-1062 10.1111/j.1528-1167.2011.03101.x
3. Berg, A. T.; Berkovic, S. F.; Brodie, M. J.; Buchhalter, J.; Cross, J. H.; van Emde Boas, W.; Engel, J.; French, J.; Glauser, T. A.; Mathern, G. W.; Moshe, S. L.; Nordli, D.; Plouin, P.; Scheffer, I. E. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009 Epilepsia 2010, 51, 676-685 10.1111/j.1528-1167.2010.02522.x
4. Willow, M.; Gonoi, T.; Catterall, W. A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells Mol. Pharmacol. 1985, 27, 549-558
5. Beydoun, A.; D'Souza, J.; Hebert, D.; Doty, P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures Expert Rev. Neurother. 2009, 9, 33-42 10.1586/14737175.9.1.33
6. Curia, G.; Biagini, G.; Perucca, E.; Avoli, M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders CNS Drugs 2009, 23, 555-568 10.2165/00023210-200923070-00002
7. Huang, C. W.; Hung, T. Y.; Wu, S. N. The inhibitory actions by lacosamide, a functionalized amino acid, on voltage-gated Na+ currents Neuroscience 2015, 287, 125-136 10.1016/j.neuroscience.2014.12.026
8. Nakatani, Y.; Masuko, H.; Amano, T. Effect of lamotrigine on Na(v)1.4 voltage-gated sodium channels J. Pharmacol. Sci. 2013, 123, 203-206 10.1254/jphs.13116SC
9. Niespodziany, I.; Leclere, N.; Vandenplas, C.; Foerch, P.; Wolff, C. Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation J. Neurosci. Res. 2013, 91, 436-443 10.1002/jnr.23136
10. Liu, G.; Yarov-Yarovoy, V.; Nobbs, M.; Clare, J. J.; Scheuer, T.; Catterall, W. A. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels Neuropharmacology 2003, 44, 413-422 10.1016/S0028-3908(02)00400-8
11. Kuo, C. C.; Lu, L. Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones Br. J. Pharmacol. 1997, 121, 1231-8 10.1038/sj.bjp.0701221
12. Xie, X.; Lancaster, B.; Peakman, T.; Garthwaite, J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones Pfluegers Arch. 1995, 430, 437-446 10.1007/BF00373920
13. Holder, J. L., Jr.; Wilfong, A. A. Zonisamide in the treatment of epilepsy Expert Opin. Pharmacother. 2011, 12, 2573-2581 10.1517/14656566.2011.622268
14. Gunthorpe, M. J.; Large, C. H.; Sankar, R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy Epilepsia 2012, 53, 412-424 10.1111/j.1528-1167.2011.03365.x
15. Main, M. J.; Cryan, J. E.; Dupere, J. R.; Cox, B.; Clare, J. J.; Burbidge, S. A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine Mol. Pharmacol. 2000, 58, 253-262
16. Dibue, M.; Kamp, M. A.; Alpdogan, S.; Tevoufouet, E. E.; Neiss, W. F.; Hescheler, J.; Schneider, T. Cav 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo Epilepsia 2013, 54, 1542-1550 10.1111/epi.12250
17. Crepeau, A. Z.; Treiman, D. M. Levetiracetam: a comprehensive review Expert Rev. Neurother. 2010, 10, 159-171 10.1586/ern.10.3
18. White, H. S. Molecular pharmacology of topiramate: managing seizures and preventing migraine Headache 2005, 45 (Suppl. 1) S48-S56 10.1111/j.1526-4610.2005.4501006.x
19. Zaccara, G.; Giovannelli, F.; Cincotta, M.; Iudice, A. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel Expert Rev. Neurother. 2013, 13, 647-655 10.1586/ern.13.46
20. Krauss, G. L.; Perucca, E.; Ben-Menachem, E.; Kwan, P.; Shih, J. J.; Squillacote, D.; Yang, H.; Gee, M.; Zhu, J.; Laurenza, A. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307 Epilepsia 2013, 54, 126-134 10.1111/j.1528-1167.2012.03648.x
21. French, J. A.; Krauss, G. L.; Steinhoff, B. J.; Squillacote, D.; Yang, H.; Kumar, D.; Laurenza, A. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305 Epilepsia 2013, 54, 117-125 10.1111/j.1528-1167.2012.03638.x
22. Hanada, T.; Hashizume, Y.; Tokuhara, N.; Takenaka, O.; Kohmura, N.; Ogasawara, A.; Hatakeyama, S.; Ohgoh, M.; Ueno, M.; Nishizawa, Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy Epilepsia 2011, 52, 1331-1340 10.1111/j.1528-1167.2011.03109.x
23. Kwan, P.; Arzimanoglou, A.; Berg, A. T.; Brodie, M. J.; Allen Hauser, W.; Mathern, G.; Moshe, S. L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies Epilepsia 2010, 51, 1069-1077 10.1111/j.1528-1167.2009.02397.x
24. Loscher, W.; Klitgaard, H.; Twyman, R. E.; Schmidt, D. New avenues for anti-epileptic drug discovery and development Nat. Rev. Drug Discovery 2013, 12, 757-776 10.1038/nrd4126
25. Loscher, W.; Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma Epilepsia 2011, 52, 657-678 10.1111/j.1528-1167.2011.03024.x
26. Schmidt, D.; Sillanpaa, M. Evidence-based review on the natural history of the epilepsies Curr. Opin. Neurol. 2012, 25, 159-163 10.1097/WCO.0b013e3283507e73
27. Lee, J. H.; Daud, A. N.; Cribbs, L. L.; Lacerda, A. E.; Pereverzev, A.; Klockner, U.; Schneider, T.; Perez-Reyes, E. Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family J. Neurosci. 1999, 19, 1912-1921
28. Perez-Reyes, E. Molecular physiology of low-voltage-activated t-type calcium channels Physiol. Rev. 2003, 83, 117-161 10.1152/physrev.00018.2002
29. Talley, E. M.; Cribbs, L. L.; Lee, J. H.; Daud, A.; Perez-Reyes, E.; Bayliss, D. A. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels J. Neurosci. 1999, 19, 1895-1911
30. Shin, H. S. T-type Ca2+ channels and absence epilepsy Cell Calcium 2006, 40, 191-196 10.1016/j.ceca.2006.04.023
31. Cheong, E.; Shin, H. S. T-type Ca(2+) channels in absence epilepsy Pfluegers Arch. 2014, 466, 719-734 10.1007/s00424-014-1461-y
32. Khosravani, H.; Zamponi, G. W. Voltage-gated calcium channels and idiopathic generalized epilepsies Physiol. Rev. 2006, 86, 941-966 10.1152/physrev.00002.2006
33. Zamponi, G. W.; Lory, P.; Perez-Reyes, E. Role of voltage-gated calcium channels in epilepsy Pfluegers Arch. 2010, 460, 395-403 10.1007/s00424-009-0772-x
34. Glauser, T. A.; Cnaan, A.; Shinnar, S.; Hirtz, D. G.; Dlugos, D.; Masur, D.; Clark, P. O.; Capparelli, E. V.; Adamson, P. C. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy N. Engl. J. Med. 2010, 362, 790-809 10.1056/NEJMoa0902014
35. Goren, M. Z.; Onat, F. Ethosuximide: from bench to bedside CNS Drug Rev. 2007, 13, 224-239 10.1111/j.1527-3458.2007.00009.x
36. Chen, Y.; Lu, J.; Pan, H.; Zhang, Y.; Wu, H.; Xu, K.; Liu, X.; Jiang, Y.; Bao, X.; Yao, Z.; Ding, K.; Lo, W. H.; Qiang, B.; Chan, P.; Shen, Y.; Wu, X. Association between genetic variation of CACNA1H and childhood absence epilepsy Ann. Neurol. 2003, 54, 239-243 10.1002/ana.10607
37. Khosravani, H.; Altier, C.; Simms, B.; Hamming, K. S.; Snutch, T. P.; Mezeyova, J.; McRory, J. E.; Zamponi, G. W. Gating effects of mutations in the Cav3.2 T-type calcium channel associated with childhood absence epilepsy J. Biol. Chem. 2004, 279, 9681-9684 10.1074/jbc.C400006200
38. Vitko, I.; Chen, Y.; Arias, J. M.; Shen, Y.; Wu, X. R.; Perez-Reyes, E. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel J. Neurosci. 2005, 25, 4844-4855 10.1523/JNEUROSCI.0847-05.2005
39. Eckle, V. S.; Shcheglovitov, A.; Vitko, I.; Dey, D.; Yap, C. C.; Winckler, B.; Perez-Reyes, E. Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility J. Physiol. 2014, 592, 795-809 10.1113/jphysiol.2013.264176
40. Heron, S. E.; Khosravani, H.; Varela, D.; Bladen, C.; Williams, T. C.; Newman, M. R.; Scheffer, I. E.; Berkovic, S. F.; Mulley, J. C.; Zamponi, G. W. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants Ann. Neurol. 2007, 62, 560-568 10.1002/ana.21169
41. Kim, D.; Song, I.; Keum, S.; Lee, T.; Jeong, M. J.; Kim, S. S.; McEnery, M. W.; Shin, H. S. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca(2+) channels Neuron 2001, 31, 35-45 10.1016/S0896-6273(01)00343-9
42. Yang, Z. Q.; Barrow, J. C.; Shipe, W. D.; Schlegel, K. A.; Shu, Y.; Yang, F. V.; Lindsley, C. W.; Rittle, K. E.; Bock, M. G.; Hartman, G. D.; Uebele, V. N.; Nuss, C. E.; Fox, S. V.; Kraus, R. L.; Doran, S. M.; Connolly, T. M.; Tang, C.; Ballard, J. E.; Kuo, Y.; Adarayan, E. D.; Prueksaritanont, T.; Zrada, M. M.; Marino, M. J.; Graufelds, V. K.; DiLella, A. G.; Reynolds, I. J.; Vargas, H. M.; Bunting, P. B.; Woltmann, R. F.; Magee, M. M.; Koblan, K. S.; Renger, J. J. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels J. Med. Chem. 2008, 51, 6471-6477 10.1021/jm800830n
43. Tringham, E.; Powell, K. L.; Cain, S. M.; Kuplast, K.; Mezeyova, J.; Weerapura, M.; Eduljee, C.; Jiang, X.; Smith, P.; Morrison, J. L.; Jones, N. C.; Braine, E.; Rind, G.; Fee-Maki, M.; Parker, D.; Pajouhesh, H.; Parmar, M.; O'Brien, T. J.; Snutch, T. P. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures Sci. Transl. Med. 2012, 4, 121ra19 10.1126/scitranslmed.3003120
44. Hosford, D. A. Models of primary generalized epilepsy Curr. Opin. Neurol. 1995, 8, 121-125 10.1097/00019052-199504000-00006
45. Coenen, A. M.; Drinkenburg, W. H.; Inoue, M.; van Luijtelaar, E. L. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats Epilepsy Res. 1992, 12, 75-86 10.1016/0920-1211(92)90029-S
46. Becker, A. J.; Pitsch, J.; Sochivko, D.; Opitz, T.; Staniek, M.; Chen, C. C.; Campbell, K. P.; Schoch, S.; Yaari, Y.; Beck, H. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy J. Neurosci. 2008, 28, 13341-13353 10.1523/JNEUROSCI.1421-08.2008
47. Matar, N.; Jin, W.; Wrubel, H.; Hescheler, J.; Schneider, T.; Weiergraber, M. Zonisamide block of cloned human T-type voltage-gated calcium channels Epilepsy Res. 2009, 83, 224-234 10.1016/j.eplepsyres.2008.11.010
48. Egan, M. F.; Zhao, X.; Smith, A.; Troyer, M. D.; Uebele, V. N.; Pidkorytov, V.; Cox, K.; Murphy, M.; Snavely, D.; Lines, C.; Michelson, D. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia Hum. Psychopharmacol. 2013, 28, 124-133 10.1002/hup.2289
49. Zamponi, G. W. Targeting voltage-gated calcium channels in neurological and psychiatric diseases Nat. Rev. Drug Discovery 2016, 15, 19-34 10.1038/nrd.2015.5
50. Choe, W.; Messinger, R. B.; Leach, E.; Eckle, V. S.; Obradovic, A.; Salajegheh, R.; Jevtovic-Todorovic, V.; Todorovic, S. M. TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent Mol. Pharmacol. 2011, 80, 900-910 10.1124/mol.111.073205
51. Francois, A.; Kerckhove, N.; Meleine, M.; Alloui, A.; Barrere, C.; Gelot, A.; Uebele, V. N.; Renger, J. J.; Eschalier, A.; Ardid, D.; Bourinet, E. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects Pain 2013, 154, 283-293 10.1016/j.pain.2012.10.023
52. Miwa, H.; Kondo, T. T-type calcium channel as a new therapeutic target for tremor Cerebellum 2011, 10 (3) 563-569 10.1007/s12311-011-0277-y
53. Handforth, A.; Homanics, G. E.; Covey, D. F.; Krishnan, K.; Lee, J. Y.; Sakimura, K.; Martin, F. C.; Quesada, A. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor Neuropharmacology 2010, 59, 380-387 10.1016/j.neuropharm.2010.05.012
54. Miwa, H.; Koh, J.; Kajimoto, Y.; Kondo, T. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats Pharmacol., Biochem. Behav. 2011, 97, 656-659 10.1016/j.pbb.2010.11.014
55. Uebele, V. N.; Gotter, A. L.; Nuss, C. E.; Kraus, R. L.; Doran, S. M.; Garson, S. L.; Reiss, D. R.; Li, Y.; Barrow, J. C.; Reger, T. S.; Yang, Z. Q.; Ballard, J. E.; Tang, C.; Metzger, J. M.; Wang, S. P.; Koblan, K. S.; Renger, J. J. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice J. Clin. Invest. 2009, 119, 1659-1667 10.1172/JCI36954
56. Uslaner, J. M.; Vardigan, J. D.; Drott, J. M.; Uebele, V. N.; Renger, J. J.; Lee, A.; Li, Z.; Le, A. D.; Hutson, P. H. T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine Biol. Psychiatry 2010, 68, 712-718 10.1016/j.biopsych.2010.05.004
57. Uslaner, J. M.; Smith, S. M.; Huszar, S. L.; Pachmerhiwala, R.; Hinchliffe, R. M.; Vardigan, J. D.; Nguyen, S. J.; Surles, N. O.; Yao, L.; Barrow, J. C.; Uebele, V. N.; Renger, J. J.; Clark, J.; Hutson, P. H. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats Neuropharmacology 2012, 62, 1413-1421 10.1016/j.neuropharm.2010.11.015
58. Xie, X.; Van Deusen, A. L.; Vitko, I.; Babu, D. A.; Davies, L. A.; Huynh, N.; Cheng, H.; Yang, N.; Barrett, P. Q.; Perez-Reyes, E. Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches Assay Drug Dev. Technol. 2007, 5, 191-203 10.1089/adt.2006.054
59. Godfraind, T.; Ertel, E. Calcium Channel Blockers; Birkhäuser: Basel, Switzerland, 2004.
60. Mishriky, N.; Asaad, F. M.; Ibrahim, Y. A.; Girgis, A. S. New 2-pyrazolines of anticipated molluscicidal activity Pharmazie 1996, 51, 544-548
61. Cox, C. D.; Breslin, M. J.; Mariano, B. J. two-step synthesis of β-alkyl chalcones and their use in the synthesis of 3,5-diaryl-5-alkyl-4,5-dihydropyrazoles Tetrahedron Lett. 2004, 45, 1489-1493 10.1016/j.tetlet.2003.12.026
62. Ritchie, T. J.; Macdonald, S. J. Physicochemical descriptors of aromatic character and their use in drug discovery J. Med. Chem. 2014, 57, 7206-7215 10.1021/jm500515d
63. Gleeson, M. P. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis J. Med. Chem. 2007, 50, 101-112 10.1021/jm060981b
64. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449 10.1021/cn100008c
65. Ertel, E. A.; Cohen, C. J. Voltage-dependent interactions: The influence and significance of membrane potential on drug-receptor interactions Drug Dev. Res. 1994, 33, 203-213 10.1002/ddr.430330304
66. Shipe, W. D.; Barrow, J. C.; Yang, Z. Q.; Lindsley, C. W.; Yang, F. V.; Schlegel, K. A.; Shu, Y.; Rittle, K. E.; Bock, M. G.; Hartman, G. D.; Tang, C.; Ballard, J. E.; Kuo, Y.; Adarayan, E. D.; Prueksaritanont, T.; Zrada, M. M.; Uebele, V. N.; Nuss, C. E.; Connolly, T. M.; Doran, S. M.; Fox, S. V.; Kraus, R. L.; Marino, M. J.; Graufelds, V. K.; Vargas, H. M.; Bunting, P. B.; Hasbun-Manning, M.; Evans, R. M.; Koblan, K. S.; Renger, J. J. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist J. Med. Chem. 2008, 51, 3692-3695 10.1021/jm800419w
67. Schlegel, K. A.; Yang, Z. Q.; Reger, T. S.; Shu, Y.; Cube, R.; Rittle, K. E.; Bondiskey, P.; Bock, M. G.; Hartman, G. D.; Tang, C.; Ballard, J.; Kuo, Y.; Prueksaritanont, T.; Nuss, C. E.; Doran, S. M.; Fox, S. V.; Garson, S. L.; Kraus, R. L.; Li, Y.; Uebele, V. N.; Renger, J. J.; Barrow, J. C. Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists Bioorg. Med. Chem. Lett. 2010, 20, 5147-5152 10.1016/j.bmcl.2010.07.010
68. Yang, Z. Q.; Schlegel, K. A.; Shu, Y.; Reger, T. S.; Cube, R.; Mattern, C.; Coleman, P. J.; Small, J.; Hartman, G. D.; Ballard, J.; Tang, C.; Kuo, Y.; Prueksaritanont, T.; Nuss, C. E.; Doran, S.; Fox, S. V.; Garson, S. L.; Li, Y.; Kraus, R. L.; Uebele, V. N.; Taylor, A. B.; Zeng, W.; Fang, W.; Chavez-Eng, C.; Troyer, M. D.; Luk, J. A.; Laethem, T.; Cook, W. O.; Renger, J. J.; Barrow, J. C. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents ACS Med. Chem. Lett. 2010, 1, 504-509 10.1021/ml100170e
69. Racine, R. J. Modification of seizure activity by electrical stimulation. II. Motor seizure Electroencephalogr. Clin. Neurophysiol. 1972, 32, 281-94 10.1016/0013-4694(72)90177-0
70. Racine, R. J. Modification of seizure activity by electrical stimulation. I. After-discharge threshold Electroencephalogr. Clin. Neurophysiol. 1972, 32, 269-279 10.1016/0013-4694(72)90176-9
71. Casillas-Espinosa, P. M.; Hicks, A.; Jeffreys, A.; Snutch, T. P.; O'Brien, T. J.; Powell, K. L. Z944, a novel selective T-type calcium channel antagonist delays the progression of seizures in the amygdala kindling model PLoS One 2015, 10, e0130012 10.1371/journal.pone.0130012